Investigating the relationship between mitochondrial genetic variation and cardiovascular-related traits to develop a framework for mitochondrial phenome-wide association studies
- Sabrina L Mitchell†1, 2,
- Jacob B Hall†1,
- Robert J Goodloe1,
- Jonathan Boston1,
- Eric Farber-Eger1,
- Sarah A Pendergrass3,
- William S Bush1, 4 and
- Dana C Crawford1, 2Email author
© Mitchell et al.; licensee BioMed Central Ltd. 2014
Received: 8 October 2013
Accepted: 5 April 2014
Published: 15 April 2014
Mitochondria play a critical role in the cell and have DNA independent of the nuclear genome. There is much evidence that mitochondrial DNA (mtDNA) variation plays a role in human health and disease, however, this area of investigation has lagged behind research into the role of nuclear genetic variation on complex traits and phenotypic outcomes. Phenome-wide association studies (PheWAS) investigate the association between a wide range of traits and genetic variation. To date, this approach has not been used to investigate the relationship between mtDNA variants and phenotypic variation. Herein, we describe the development of a PheWAS framework for mtDNA variants (mt-PheWAS). Using the Metabochip custom genotyping array, nuclear and mitochondrial DNA variants were genotyped in 11,519 African Americans from the Vanderbilt University biorepository, BioVU. We employed both polygenic modeling and association testing with mitochondrial single nucleotide polymorphisms (mtSNPs) to explore the relationship between mtDNA variants and a group of eight cardiovascular-related traits obtained from de-identified electronic medical records within BioVU.
Using polygenic modeling we found evidence for an effect of mtDNA variation on total cholesterol and type 2 diabetes (T2D). After performing comprehensive mitochondrial single SNP associations, we identified an increased number of single mtSNP associations with total cholesterol and T2D compared to the other phenotypes examined, which did not have more significantly associated SNPs than would be expected by chance. Among the mtSNPs significantly associated with T2D we identified variant mt16189, an association previously reported only in Asian and European-descent populations.
Our replication of previous findings and identification of novel associations from this initial study suggest that our mt-PheWAS approach is robust for investigating the relationship between mitochondrial genetic variation and a range of phenotypes, providing a framework for future mt-PheWAS.
KeywordsMitochondrial DNA variation mtSNP PheWAS GCTA Mixed modeling Polygenic analysis
As the primary energy producers of the cell, mitochondria are critical to cellular fitness. While energy production is the function most often associated with mitochondria, the organelle plays a vital role in other cellular processes including cholesterol synthesis, fatty acid oxidation, ammonia detoxification, calcium homeostasis, and apoptosis, suggesting that mitochondrial dysfunction could have far-reaching effects. Indeed, mitochondrial dysfunction has been observed in a variety of diseases, including amyotrophic lateral sclerosis (ALS), Huntington’s disease, Alzheimer’s disease, and various types of cancer.
Mitochondria maintain their own DNA separate from the nuclear genome. The human mitochondrial genome consists of a double-stranded, circular chromosome spanning 16,569 base pairs. This maternally inherited, compact genome contains 37 genes encoding 2 ribosomal RNAs, 22 transfer RNAs, and 13 protein-encoding genes that are essential components of the oxidative phosphorylation complexes. Rare mutations in mitochondrial DNA (mtDNA) give rise to a spectrum of diseases, including Leber’s Hereditary Optic Neuropathy (LHON), Myoclonic Epilepsy with Ragged Red Fibers (MERRF), Maternally Inherited Diabetes and Deafness (MIDD), and prostate cancer. Common mtDNA variation has also has been associated with common complex diseases, including type 2 diabetes (T2D)[3, 4], multiple cancers, Alzheimer’s, and Parkinson’s. Furthermore, mitochondrial single nucleotide polymorphisms (mtSNPs) have been associated with quantitative trait variance among phenotypes, such as triglycerides and HDL-C, both known to play a role in cardiovascular disease. The range of phenotypes associated with mtDNA variation underscores the pleiotropic nature of mitochondrial genetic variation.
Phenome-Wide Association Studies (PheWAS) have been used to explore the association between nuclear single nucleotide polymorphisms (SNPs) and a wide array of phenotypes. To date, PheWAS have successfully used electronic-medical record (EMR) data and large population-based survey data[10–15] to replicate previously reported genome-wide association study (GWAS) findings, as well as to uncover intriguing novel associations. These studies have also identified potential pleiotropy, in which single SNPs are associated with multiple phenotypes. However, thus far, the PheWAS approach has not been used to explore the relationship between mitochondrial SNPs (mtSNPs) and multiple phenotypes.
While there has been some research focused on identifying the impact of mtDNA variants on a number of complex traits, this relationship has been primarily explored through association testing with single traits or outcomes. Further work is needed to better characterize the relationship between mitochondrial genetic variation and a wide range of outcomes; this can be done by applying the PheWAS approach. Thus, the goal of this work was to develop a framework for implementing a mitochondrial PheWAS (mt-PheWAS). A method yet to be explored for characterizing the relationship between mitochondrial variation and phenotypes, in a PheWAS context, is the use of polygenic modeling, which can provide an estimate of heritability by considering the amount of phenotypic variation explained by genotypic variation. In this work, we demonstrate the utility of polygenic modeling for prioritizing phenotypic outcomes prior to pursuing mtSNP association analysis using a PheWAS approach. Within this framework, polygenic modeling, as well as haplogroup and mtSNP association tests can be used singly or in combination to explore the relationship between mtDNA variation and a range of phenotypes in the context of mt-PheWAS. Applying the PheWAS approach will allow for hypothesis-generation about the role of mtDNA variation in human health and disease.
To test our mt-PheWAS framework, we explored the relationship between mtDNA variation and eight cardiovascular-related phenotypes using Metabochip genotype data from African Americans in the Vanderbilt University biorepository, BioVU. We began with a polygenic approach, employing mixed linear modeling to investigate the overall contribution of mitochondrial genetic variation on trait variance. Single mtSNP association analysis was then performed with all eight traits to identify specific genotype-phenotype associations. Using the polygenic approach we identified two traits with evidence for association with mitochondrial genetic variation. Our single mtSNP association analysis confirmed the correlation between the number of significant mtSNPs observed for each trait and the overall proportion of trait variance explained by mitochondrial genetic variation, suggesting that our proposed mt-PheWAS framework, which includes a phenotype filtering step via polygenic modeling, is a valid approach for investigating the effect of mtDNA variation for a range of phenotypes.
Study population and phenotypes
The Vanderbilt University Medical Center (VUMC) biorepository, BioVU, contains more than 170,000 individual de-identified DNA samples linked to a de-identified version of the EMR, known as the synthetic derivative. As part of the Population Architecture using Genomics and Epidemiology I (PAGE I) study, the Epidemiologic Architecture for Genes Linked to Environment (EAGLE) study has genotyped 15,863 BioVU samples (EAGLE BioVU) consisting of individuals 18 years and older from diverse populations, including 11,519 African Americans. All samples were genotyped on the Metabochip, a custom genotyping array containing 196,725 SNPs, the majority of which were chosen based on previous associations with metabolic, cardiovascular, and anthropometric traits, as well as to fine map the regions around these previously associated variants. Among the variants on the Metabochip are 135 mtSNPs, including a putative T2D mtSNP and a rare MIDD mutation[19, 20]. Genotyping was performed by the Center for Human Genetics DNA Resources Core at VUMC, and quality control was performed as previously described, resulting in 192,139 autosomal SNPs and 130 mtSNPs for use in this analysis.
Characteristics of study population
Sex (% female)
Body Mass Index (kg/m2)
Total Cholesterol (mg/dL)
Mean Corpuscular Hemoglobin (pg/cell)
Type 2 Diabetes (Cases/Controls)
We performed polygenic analysis using mixed-modeling to determine the overall contribution of mitochondrial genetic variation captured by the Metabochip to the variance of the eight selected traits. By first using polygenic modeling, phenotypes can be prioritized or filtered based on putative contribution of mtDNA variation, assuming that a lack of evidence for influence of mtDNA variation implies a reduced chance of identifying specific single mtSNP associations. Genome-wide Complex Trait Analysis (GCTA), which employs a mixed linear model to estimate the overall impact of genetic variation on trait variance, was used for the polygenic analysis. A key component of GCTA is its use of a genetic relationship matrix (GRM) to estimate pair-wise relatedness using a collection of genotypes within a dataset, based on additive genetic effects. However, as opposed to the diploid nuclear genome, the mitochondrial genome is haploid, so mitochondrial GRMs are calculated based on allelic sharing, rather than additive effects. Unlike typical GWAS, in which the effects of single SNPs are calculated independently, GCTA evaluates the relative levels of genomic sharing between individuals, creating a GRM and associating this relatedness to quantitative trait variation or binary trait risk.
For each trait, GCTA was used to fit a mixed linear model and estimate the proportion of variance explained (PVE) by nuclear and mitochondrial genetic variation. Mixed models consist of fixed and random effects. Here, the fixed effects included age, sex, and the first two nuclear principal components (PCs) as covariates. Eigenstrat was used to generate nuclear PCs from the 192,139 autosomal SNPs that passed QC. The random effect is empirical genetic relatedness, which was estimated using GRMs, created via GCTA, for the nuclear and mitochondrial genomes, using 192,139 and 130 SNPs, respectively.
Expectation-maximization (EM), the iterative method for finding the maximum likelihood estimate, was used for restricted maximum likelihood (REML) analysis using GCTA. REML provides estimates of the proportion of trait variance explained by genetic variation in the nuclear and/or mitochondrial genome. A likelihood ratio test (LRT) was performed comparing full and reduced models to determine the significance of mitochondrial genetic variation on the overall mixed linear model for each trait. The likelihood ratio test measures the significance of a specific model component. The full model contained both a nuclear and mitochondrial GRM, while the reduced model contained only a nuclear GRM. Here, we used the likelihood ratio test to evaluate the contribution of mitochondrial genetic variation captured by the Metabochip to the phenotypic variation or risk observed in the selected cardiovascular-related traits.
Single mtSNP analysis
We performed single mtSNP analysis for all traits to determine if filtering based on results from our polygenic analysis was beneficial. We excluded 44 mtSNPs with a minor allele frequency less than 1%, leaving 86 mtSNPs available for the single mtSNP association analysis. PLINK was used to perform linear or logistic regression for continuous and binary traits, respectively, to investigate mtSNP-phenotype associations. Both linear and logistic regression models were adjusted for age, sex, and the first two nuclear PCs. Haplogroup association analysis was not carried out in this study. While the mtDNA coverage on the Metabochip can be used to infer haplogroups, it is more reliable for classifying populations of European descent than for other ancestries due to the percent mitochondrial genetic variation captured[19, 20].
Single mtSNP tests of association
The goal of this work was to perform an exploratory analysis to establish a framework for mt-PheWAS for investigating the relationship between mtDNA variation and a range of phenotypes. We first employed a polygenic approach to investigate the global effect of mtDNA variation on phenotypic variance for eight cardiovascular-related traits. Given the metabolic trait focus of the nuclear SNP content on the Metabochip and the nature of the selected phenotypes in this study, we expected the polygenic analysis would reveal significant proportion of trait variance explained. However, overall, we observed relatively low PVE for both nuclear and mitochondrial genetic variation. Only a single trait, total cholesterol, reached statistical significance in the polygenic analysis, although T2D approached the statistical significance threshold of p < 0.05. The low PVE may be due, in part, to the targeted nature of the Metabochip which does not contain a genome-wide distribution of SNPs that can be found on GWAS genotyping arrays.
We also performed single mtSNP association analysis to identify mitochondrial genotype-phenotype associations, and to relate the number of significant mtSNPs to the observed mitochondrial PVE for all phenotypes. We found that total cholesterol and T2D, which exhibited the most evidence for a contribution of mitochondrial genetic variation to trait variance or risk, had the highest number of significantly associated mtSNPs. Interestingly, there was some evidence for pleiotropy based on overlap of significantly associated mtSNPs between traits; for example, three mtSNPs (mt14152, mt15670, and mt15942) were significantly associated with both total cholesterol and T2D (Additional file2).
Studies report inconsistent results on the role of mitochondrial genetic variation in T2D. In the present study we identified 13 mtDNA SNPs associated with T2D in African Americans including variant mt16189, which was previously shown to be correlated with fasting insulin concentration, fasting glucose, and BMI, and has been associated with T2D in both Asian and European-descent populations. To our knowledge, this is the first reported association of mt16189 with T2D in an African-descent population.
Notably, five of the mtSNPs (mt9072, mt12810, mt13845, mt14000, and mt14911) associated with T2D in our population are common to the African mitochondrial haplogroup L1c. This haplogroup has previously been associated with peripheral neuropathy in HIV patients receiving anti-retroviral therapy in two separate study populations, although with opposite directions of effect[30, 31]. Holzinger et al. report a decreased risk of peripheral neuropathy in individuals with the L1c haplogroup. Peripheral neuropathy is a common comorbidity in patients with diabetes and is generally linked to poor control of blood sugar. Our results indicate that mitochondrial haplogroup L1c is associated with decreased risk of T2D. Taken together these data suggest that mitochondrial DNA variation plays a role in both T2D and peripheral neuropathy.
Three mtSNPs (mt14152, mt15670, mt15942) significantly associated with increased risk of T2D in our population are found on the L3e1 African mitochondrial haplogroup which has previously been associated with hypertriglyceridemia in black South Africans on anti-retroviral therapy. Given that high triglyceride levels are associated with increased risk for T2D, this is consistent with our finding that mtSNPs from the L3e1 haplogroup background are associated with increased risk of T2D. We also identified associations between these three SNPs and total cholesterol; however they were negatively correlated with total cholesterol.
While we were successful in establishing a mt-PheWAS framework for future EAGLE and PAGE I studies, our framework is not without limitations. First, the PheWAS approach, even when applied to large datasets such as EAGLE BioVU, can be limited in sample size and thus potentially power depending on the outcomes included in the study. This mt-PheWAS is no exception as the sample sizes available for analysis varied from 1,338 cases of T2D to 9,559 subjects for MCH. Additional limitations of the PheWAS approach include the high-throughput manner in which phenotypes are defined, and that regression models are only minimally adjusted for standard covariates. Because the mt-PheWAS analyses presented herein were exploratory in nature we did not correct for multiple testing. Further work will be necessary for external replication and validation of these results. Finally, as previously mentioned, this present study is limited to genotypic data from the Illumina Metabochip, a custom array designed for fine-mapping specific GWAS-identified regions previously associated with specific phenotypes identified from mostly European-descent populations. The mitochondrial variants included on the Metabochip are also limited, impacting our ability to determine haplogroups for the samples in this study.
We outlined and tested a framework for performing mt-PheWAS to investigate the relationship between mitochondrial genetic variation and a range of phenotypes. We characterized the utility of polygenic modeling as a method for prioritizing phenotypes for PheWAS by performing both polygenic modeling and comprehensive single mtSNP association testing for a group of eight metabolic traits. Further, we identified multiple single mtSNP associations for total cholesterol and T2D. Our data indicate that, despite relatively limited mtSNP coverage, the Illumina Metabochip is useful in identifying mitochondrial genotype-phenotype associations. Our results also demonstrate that the EAGLE mt-PheWAS framework is capable of identifying known genetic associations and has the potential to uncover novel associations contributing to the complex relationship between human health and mitochondrial genetic variation.
Body mass index
Epidemiologic architecture for genes linked to environment
Genome-wide complex trait analysis
Genetic relationship matrix
Genome-wide association study
High-density lipoprotein cholesterol
Low-density lipoprotein cholesterol
Likelihood ratio test
Mean corpuscular hemoglobin
Mitochondrial deoxyribonucleic acid
Mitochondrial phenome-wide association study
Mitochondrial single nucleotide polymorphism
Population architecture using genomics and epidemiology
Phenome-wide association study
Proportion of variance explained
Single nucleotide polymorphism
Type 2 diabetes.
The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center’s BioVU which is supported by institutional funding and by the Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH. This work is supported in part by NIH U01 HG004798 and its ARRA supplements. The Vanderbilt University Center for Human Genetics Research, Computational Genomics Core provided computational and/or analytical support for this work.
- De Moura MB, dos Santos LS, Van Houten B: Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen. 2010, 51: 391-405.PubMedGoogle Scholar
- Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF: Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res. 2002, 62: 6470-6474.PubMedGoogle Scholar
- Wang D, Taniyama M, Suzuki Y, Katagiri T, Ban Y: Association of the mitochondrial DNA 5178A/C polymorphism with maternal inheritance and onset of type 2 diabetes in Japanese patients. Exp Clin Endocrinol Diabetes. 2001, 109: 361-364. 10.1055/s-2001-17407.View ArticlePubMedGoogle Scholar
- Tang D-L, Zhou X, Li X, Zhao L, Liu F: Variation of mitochondrial gene and the association with type 2 diabetes mellitus in a Chinese population. Diabetes Res Clin Pract. 2006, 73: 77-82. 10.1016/j.diabres.2005.12.001.View ArticlePubMedGoogle Scholar
- Brandon M, Baldi P, Wallace DC: Mitochondrial mutations in cancer. Oncogene. 2006, 25: 4647-4662. 10.1038/sj.onc.1209607.View ArticlePubMedGoogle Scholar
- Van der Walt JM, Dementieva YA, Martin ER, Scott WK, Nicodemus KK, Kroner CC, Welsh-Bohmer KA, Saunders AM, Roses AD, Small GW, Schmechel DE, Murali Doraiswamy P, Gilbert JR, Haines JL, Vance JM, Pericak-Vance MA: Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett. 2004, 365: 28-32. 10.1016/j.neulet.2004.04.051.View ArticlePubMedGoogle Scholar
- Van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM: Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003, 72: 804-811. 10.1086/373937.View ArticlePubMedPubMed CentralGoogle Scholar
- Hegele RA, Zinman B, Hanley AJ, Harris S, Connelly PW: A common mtDNA polymorphism associated with variation in plasma triglyceride concentration. Am J Hum Genet. 1997, 60: 1552-1555. 10.1016/S0002-9297(07)64252-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Kokaze A, Ishikawa M, Matsunaga N, Yoshida M, Sekine Y, Teruya K, Takeda N, Sumiya Y, Uchida Y, Takashima Y: Association of the mitochondrial DNA 5178 A/C polymorphism with serum lipid levels in the Japanese population. Hum Genet. 2001, 109: 521-525. 10.1007/s004390100602.View ArticlePubMedGoogle Scholar
- Pendergrass SA, Brown-Gentry K, Dudek S, Frase A, Torstenson ES, Goodloe R, Ambite JL, Avery CL, Buyske S, Bůžková P, Deelman E, Fesinmeyer MD, Haiman CA, Heiss G, Hindorff LA, Hsu C-N, Jackson RD, Kooperberg C, Le Marchand L, Lin Y, Matise TC, Monroe KR, Moreland L, Park SL, Reiner A, Wallace R, Wilkens LR, Crawford DC, Ritchie MD: Phenome-wide association study (PheWAS) for detection of pleiotropy within the population architecture using genomics and epidemiology (PAGE) network. PLoS Genet. 2013, 9: e1003087-10.1371/journal.pgen.1003087.View ArticlePubMedPubMed CentralGoogle Scholar
- Pendergrass SA, Brown-Gentry K, Dudek SM, Torstenson ES, Ambite JL, Avery CL, Buyske S, Cai C, Fesinmeyer MD, Haiman C, Heiss G, Hindorff LA, Hsu C-N, Jackson RD, Kooperberg C, Le Marchand L, Lin Y, Matise TC, Moreland L, Monroe K, Reiner AP, Wallace R, Wilkens LR, Crawford DC, Ritchie MD: The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet Epidemiol. 2011, 35: 410-422. 10.1002/gepi.20589.View ArticlePubMedPubMed CentralGoogle Scholar
- Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, Wang D, Masys DR, Roden DM, Crawford DC: PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010, 26: 1205-1210. 10.1093/bioinformatics/btq126.View ArticlePubMedPubMed CentralGoogle Scholar
- Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM, Ramirez AH, Bowton E, Basford MA, Carrell DS, Peissig PL, Kho AN, Pacheco JA, Rasmussen LV, Crosslin DR, Crane PK, Pathak J, Bielinski SJ, Pendergrass SA, Xu H, Hindorff LA, Li R, Manolio TA, Chute CG, Chisholm RL, Larson EB, Jarvik GP, Brilliant MH: Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013, 31: 1102-1110. 10.1038/nbt.2749.View ArticlePubMedPubMed CentralGoogle Scholar
- Shameer K, Denny JC, Ding K, Jouni H, Crosslin DR, de Andrade M, Chute CG, Peissig P, Pacheco JA, Li R, Bastarache L, Kho AN, Ritchie MD, Masys DR, Chisholm RL, Larson EB, McCarty CA, Roden DM, Jarvik GP, Kullo IJ: A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet. 2014, 133: 95-109. 10.1007/s00439-013-1355-7.View ArticlePubMedGoogle Scholar
- Hebbring SJ, Schrodi SJ, Ye Z, Zhou Z, Page D, Brilliant MH: A PheWAS approach in studying HLA-DRB1*1501. Genes Immun. 2013, 14: 187-191. 10.1038/gene.2013.2.View ArticlePubMedPubMed CentralGoogle Scholar
- Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW: Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet. 2013, 14: 483-495. 10.1038/nrg3461.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang J, Lee SH, Goddard ME, Visscher PM: GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011, 88: 76-82. 10.1016/j.ajhg.2010.11.011.View ArticlePubMedPubMed CentralGoogle Scholar
- Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, Masys DR: Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008, 84: 362-369. 10.1038/clpt.2008.89.View ArticlePubMedPubMed CentralGoogle Scholar
- Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, Chines PS, Burtt NP, Fuchsberger C, Li Y, Erdmann J, Frayling TM, Heid IM, Jackson AU, Johnson T, Kilpeläinen TO, Lindgren CM, Morris AP, Prokopenko I, Randall JC, Saxena R, Soranzo N, Speliotes EK, Teslovich TM, Wheeler E, Maguire J, Parkin M, Potter S, Rayner NW, Robertson N, Stirrups K: The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet. 2012, 8: e1002793-10.1371/journal.pgen.1002793.View ArticlePubMedPubMed CentralGoogle Scholar
- Saxena R, de Bakker PIW, Singer K, Mootha V, Burtt N, Hirschhorn JN, Gaudet D, Isomaa B, Daly MJ, Groop L, Ardlie KG, Altshuler D: Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. Am J Hum Genet. 2006, 79: 54-61. 10.1086/504926.View ArticlePubMedPubMed CentralGoogle Scholar
- Buyske S, Wu Y, Carty CL, Cheng I, Assimes TL, Dumitrescu L, Hindorff LA, Mitchell S, Ambite JL, Boerwinkle E, Buzkova P, Carlson CS, Cochran B, Duggan D, Eaton CB, Fesinmeyer MD, Franceschini N, Haessler J, Jenny N, Kang HM, Kooperberg C, Lin Y, Le Marchand L, Matise TC, Robinson JG, Rodriguez C, Schumacher FR, Voight BF, Young A, Manolio TA: Evaluation of the metabochip genotyping array in African Americans and implications for fine mapping of GWAS-identified loci: the PAGE study. PLoS One. 2012, 7: e35651-10.1371/journal.pone.0035651.View ArticlePubMedPubMed CentralGoogle Scholar
- Kho AN, Hayes MG, Rasmussen-Torvik L, Pacheco JA, Thompson WK, Armstrong LL, Denny JC, Peissig PL, Miller AW, Wei W-Q, Bielinski SJ, Chute CG, Leibson CL, Jarvik GP, Crosslin DR, Carlson CS, Newton KM, Wolf WA, Chisholm RL, Lowe WL: Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc. 2012, 19: 212-218. 10.1136/amiajnl-2011-000439.View ArticlePubMedGoogle Scholar
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007, 81: 559-575. 10.1086/519795.View ArticlePubMedPubMed CentralGoogle Scholar
- Pendergrass SA, Dudek SM, Crawford DC, Ritchie MD: Synthesis-view: visualization and interpretation of SNP association results for multi-cohort, multi-phenotype data and meta-analysis. BioData Min. 2010, 3: 10-10.1186/1756-0381-3-10.View ArticlePubMedPubMed CentralGoogle Scholar
- Poulton J, Brown MS, Cooper A, Marchington DR, Phillips DI: A common mitochondrial DNA variant is associated with insulin resistance in adult life. Diabetologia. 1998, 41: 54-58. 10.1007/s001250050866.View ArticlePubMedGoogle Scholar
- Kim JH, Park KS, Cho YM, Kang BS, Kim SK, Jeon HJ, Kim SY, Lee HK: The prevalence of the mitochondrial DNA 16189 variant in non-diabetic Korean adults and its association with higher fasting glucose and body mass index. Diabet Med. 2002, 19: 681-684. 10.1046/j.1464-5491.2002.00747.x.View ArticlePubMedGoogle Scholar
- Park KS, Chan JC, Chuang L-M, Suzuki S, Araki E, Nanjo K, Ji L, Ng M, Nishi M, Furuta H, Shirotani T, Ahn BY, Chung SS, Min H-K, Lee SW, Kim JH, Cho YM, Lee HK: A mitochondrial DNA variant at position 16189 is associated with type 2 diabetes mellitus in Asians. Diabetologia. 2008, 51: 602-608. 10.1007/s00125-008-0933-z.View ArticlePubMedGoogle Scholar
- Poulton J, Luan J, Macaulay V, Hennings S, Mitchell J, Wareham NJ: Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case–control study. Hum Mol Genet. 2002, 11: 1581-1583. 10.1093/hmg/11.13.1581.View ArticlePubMedGoogle Scholar
- Van Oven M, Kayser M: Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. Hum Mutat. 2009, 30: E386-E394. 10.1002/humu.20921.View ArticlePubMedGoogle Scholar
- Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T: African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis. 2010, 201: 1703-1707. 10.1086/652419.View ArticlePubMedPubMed CentralGoogle Scholar
- Holzinger ER, Hulgan T, Ellis RJ, Samuels DC, Ritchie MD, Haas DW, Kallianpur AR, Bloss CS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Franklin DR, Rosario D, Selph D, Letendre S, Grant I: Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012, 18: 511-520. 10.1007/s13365-012-0133-y.View ArticlePubMedPubMed CentralGoogle Scholar
- Oyibo SO, Prasad YDM, Jackson NJ, Jude EB, Boulton AJM: The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002, 19: 870-873. 10.1046/j.1464-5491.2002.00801.x.View ArticlePubMedGoogle Scholar
- Sinxadi PZ, Dave JA, Samuels DC, Heckmann JM, Maartens G, Levitt NS, Wester CW, Haas DW, Hulgan T: Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study. AIDS Res Hum Retroviruses. 2013, 29: 1031-1039. 10.1089/aid.2012.0373.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.